CSIMarket Company Name, Ticker, Customers, else..
 
Nuvectis Pharma inc   (NASDAQ: NVCT)
 
Price: $22.7300 $-1.00 -4.214%
Day's High: $24.350000381469727 Week Perf: -12.21 %
Day's Low: $ 22.59 30 Day Perf: 5.62 %
Volume (M): 192,552 52 Wk High: $ 29.27
Volume (M$): $ 0 52 Wk Avg: $10.54
Open: $23.52 52 Wk Low: $5.55



 Market Capitalization (Millions $) 534
 Shares Outstanding (Millions) 23
 Employees 13
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -30
 Cash Flow (TTM) (Millions $) -2
 Capital Exp. (TTM) (Millions $) 0

Business Description


Nuvectis Pharma Inc is a pharmaceutical company that focuses on the development and commercialization of innovative therapies for various medical conditions. The company is dedicated to improving patient outcomes and addressing unmet medical needs. With a team of experienced scientists and researchers, Nuvectis Pharma works to discover and develop novel drugs, leveraging cutting-edge technologies and scientific advancements. The company aims to bring safe and effective treatments to market, ultimately improving the quality of life for patients worldwide.


   Company Address: 1 Bridge Plaza, Fort Lee, 7024 NJ
   Company Phone Number: 614-3150   Stock Exchange / Ticker: NASDAQ NVCT


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ADIL        6.48% 
IBIO   -10.56%    
MRKR   -11.33%    
NRIX   -1.87%    
RYTM   -4.76%    
VTGN        6.25% 
• View Complete Report
   



Clinical Study

Nuvectis Pharma Advancements in NSCLC Treatment Amidst Financial Challenges

Published Sat, Jun 14 2025 7:25 PM UTC

In a significant stride towards improving the treatment landscape for non-small cell lung cancer (NSCLC), Nuvectis Pharma has announced the publication of a research study conducted at the Lerner Research Institute, part of the Cleveland Clinic at Case Western Reserve University. The study highlights the potential of the combination of NXP900 and epidermal growth factor rece...
Business Update

Nuvectis Pharma Shows Promise in NSCLC Treatment Despite Revenue Challenges

Published Sat, Mar 8 2025 9:24 AM UTC

In a recent announcement, Nuvectis Pharma (NASDAQ: NVCT) reported encouraging findings from a study conducted at the Cleveland Clinic s Lerner Research Institute. The study, published in the peer-reviewed journal Molecular Cancer Research, evaluated the efficacy of NXP900, a novel therapeutic candidate, in combination with osimertinib (Tagrisso) for the treatment of non-smal...
Clinical Study

A Pioneering Advance in Oncological Pharmacology The Granting of Orphan Drug Designation for NXP800

Published Thu, Aug 29 2024 12:01 PM UTC

In the evolving landscape of oncological therapeutics, the recent announcement from Nuvectis Pharma, Inc. regarding the Orphan Drug Designation granted by the venerable United States Food and Drug Administration (FDA) merits commendation and thorough examination. This notable designation pertains to NXP800, an emergent pharmacological agent designated for the treatment of ma...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 58.75
PEG (TTM) -

Financial Strength Current
Quick Ratio 1.67
Working Capital Ratio 1.68
Leverage Ratio (MRQ) 1.46
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -1.34 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 0.94 $
Book Value 0.39 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -2,328,846
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.